There are many people around the world who are infected with the Hepatitis B every year. Hepatitis B is a serious viral infection, that attacks the liver and can even cause lifelong infection, liver scarring, which is also known as cirrhosis, and eventually liver cancer, liver failure and death. But now, the U.S. FDA has approved a new therapy for chronic hepatitis B, which goes by the name of Tyzeka by the Drug manufacturing company Novartis.
Tyzeka by Novartis is not a cure, but can help to suppress the hepatitis B virus and reduce the liver inflammation that usually accompanies the disease. As of now there are six FDA-approved drugs to treat Hepatitis B.
Hepatitis B can spread through infected blood, mainly during unprotected sex, childbirth or through sharing or reuse of hypodermic needles.
Novartis, the Swiss drug company who manufactures Tyzeka warns of its side effects, which include elevated levels of an enzyme responsible for the breakdown of muscle tissue, upper respiratory tract infection, headaches, fatigue, abdominal pain and cough.